J Breast Cancer.  2022 Feb;25(1):49-56. 10.4048/jbc.2022.25.e1.

CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With FamTrastuzumab Deruxtecan: A Single Institutional Experience

• Jang YJ
• Jeong JH
• Kim JE
• Ahn JH
• Jung KH
• Kim SB

• KMID: 2526723
• DOI: http://doi.org/10.4048/jbc.2022.25.e1

Abstract

This single-institute, retrospective cohort study enrolled patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with trastuzumab deruxtecan between August 2017 and January 2021 from four previous studies. Of 31 patients, 4 (12.9%) had interstitial lung disease (ILD). The dominant pattern observed on computed tomography was organizing pneumonia (100%), comprising subpleural consolidations in the lung periphery. However, no dominant distribution was observed in radiological lesions of the lungs. Of all the tested patients, lower lobe predominance was noted in 2 (50.0%) patients, upper lobe predominance in 1 (25.0%) patient, and diffused lobe distribution in 1 (25.0%) patient. All events were confined to the Common Terminology Criteria for Adverse Events grade 1 or 2 (100%). None of the patients died. Despite the small number of cases investigated, the incidence of trastuzumab deruxtecan-induced ILD in the Korean population was comparable to that previously reported.

Keyword

Breast Neoplasms; Genes; erbB-2; Lung Diseases; Interstitial; Tomography; X-ray Computed; Trastuzumab